MDSpire - Summary
Commentary & Perspectives

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...

Share

Derek Raghavan, MD, PhD, discusses the contentious issue of prostate-specific antigen (PSA) screening for prostate cancer, highlighted by a recent TV advertisement celebrating its benefits. Despite claims of life-saving outcomes, experts criticize the lack of overall survival benefits demonstrated in the European Prostate Cancer Study, questioning the utility of PSA in early-stage detection and its potential to cause harm. The commentary advocates for a balanced health policy regarding PSA screening amidst ongoing confusion in medical practice.

Original Source(s)

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

  • by Derek Raghavan

  • March 31, 2026

Related Content

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...

Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC

Radiopharmaceutical therapy is rapidly reshaping the treatment landscape for advanced prostate cancer.

  • by

  • March 31, 2026

  • 3 min
It's Like PCR, But Better

Geoff Smith introduces the mcPCR method for methylated DNA analysis that is expanding the potential of epigenetics for disease detection